Amphastar Pharmaceuticals, through its wholly owned UK subsidiary, Amphastar UK Limited, acquired a UK-based corporation, International Medication Systems (UK) Limited, including its product trademarks, and other related product assets, as well as marketing authorizations for thirty-three products in the UK, Ireland, Australia, and New Zealand, representing eleven different injectable chemical entities, from UCB Pharma GmbH for $7.7 million. The products are generic injectables containing the fo...